XERIS BIOPHARMA HLDGS INC COM USD0.0001XERIS BIOPHARMA HLDGS INC COM USD0.0001XERIS BIOPHARMA HLDGS INC COM USD0.0001

XERIS BIOPHARMA HLDGS INC COM USD0.0001

No trades
See on Supercharts
Market capitalization
‪247.20 M‬USD
−0.453USD
‪−62.26 M‬USD
‪163.91 M‬USD
‪125.57 M‬
Beta (1Y)
1.19

About XERIS BIOPHARMA HLDGS INC COM USD0.0001

CEO
Paul R. Edick
Headquarters
Chicago
Employees (FY)
377
Founded
2005
ISIN
US98422E1038
FIGI
BBG012YNKCH9
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 0A8E is 1.700 USD — it has decreased by 4.76% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange XERIS BIOPHARMA HLDGS INC COM USD0.0001 stocks are traded under the ticker 0A8E.
XERIS BIOPHARMA HLDGS INC COM USD0.0001 is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
0A8E stock is 5.00% volatile and has beta coefficient of 1.19. Check out the list of the most volatile stocks — is XERIS BIOPHARMA HLDGS INC COM USD0.0001 there?
One year price forecast for XERIS BIOPHARMA HLDGS INC COM USD0.0001 has a max estimate of 6.000 USD and a min estimate of 4.000 USD.
0A8E earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.10 USD resulting in a 13.94% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about XERIS BIOPHARMA HLDGS INC COM USD0.0001 earnings.
XERIS BIOPHARMA HLDGS INC COM USD0.0001 revenue for the last quarter amounts to ‪48.32 M‬ USD despite the estimated figure of ‪40.64 M‬ USD. In the next quarter revenue is expected to reach ‪43.17 M‬ USD.
Yes, you can track XERIS BIOPHARMA HLDGS INC COM USD0.0001 financials in yearly and quarterly reports right on TradingView.
0A8E stock has fallen by 15.76% compared to the previous week, the month change is a 19.62% fall, over the last year XERIS BIOPHARMA HLDGS INC COM USD0.0001 has showed a 23.70% decrease.
0A8E net income for the last quarter is ‪−13.39 M‬ USD, while the quarter before that showed ‪−12.19 M‬ USD of net income which accounts for −9.85% change. Track more XERIS BIOPHARMA HLDGS INC COM USD0.0001 financial stats to get the full picture.
Today XERIS BIOPHARMA HLDGS INC COM USD0.0001 has the market capitalization of ‪247.20 M‬, it has decreased by 3.35% over the last week.
No, 0A8E doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0A8E shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XERIS BIOPHARMA HLDGS INC COM USD0.0001 stock right from TradingView charts — choose your broker and connect to your account.
0A8E reached its all-time high on Jun 25, 2021 with the price of 4.760 USD, and its all-time low was 0.970 USD and was reached on Jan 5, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 20, 2024, the company has 377.00 employees. See our rating of the largest employees — is XERIS BIOPHARMA HLDGS INC COM USD0.0001 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XERIS BIOPHARMA HLDGS INC COM USD0.0001 technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XERIS BIOPHARMA HLDGS INC COM USD0.0001 stock shows the sell signal. See more of XERIS BIOPHARMA HLDGS INC COM USD0.0001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on XERIS BIOPHARMA HLDGS INC COM USD0.0001 future price: according to them, 0A8E price has a max estimate of 6.00 USD and a min estimate of 4.00 USD. Read a more detailed XERIS BIOPHARMA HLDGS INC COM USD0.0001 forecast: see what analysts think of XERIS BIOPHARMA HLDGS INC COM USD0.0001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XERIS BIOPHARMA HLDGS INC COM USD0.0001 EBITDA is ‪−30.85 M‬ USD, and current EBITDA margin is −18.82%. See more stats in XERIS BIOPHARMA HLDGS INC COM USD0.0001 financial statements.